




# Advancing Recognition, Intervention, and Assessment of ARIA to Optimize the Therapeutic Potential of Anti-Amyloid Therapies for Patients With Alzheimer's Disease



Anti-amyloid treatment can be an option only if positive amyloid status is confirmed by amyloid PET scan or CSF analysis. For eligible patients who have collaboratively decided to move forward with treatment, initiate and manage therapy according to appropriate use recommendation protocols as outlined below.



ARIA = amyloid-related imaging abnormalities; CSF = cerebrospinal fluid; MRI = magnetic resonance imaging; PET = positron emission tomography.

**REFERENCES**

- Alzheimer's Association. Donanemab Appropriate Use Recommendations. <https://pro.alz.org/files/download/DBB34343-2DOC-42BF-9101-42A32583CA37.pdf> Accessed 01/30/2026
- Cummings J, et al. *J Prev Alzheimers Dis.* 2023;10:362-377. <https://doi.org/10.14283/jpad.2023.30>
- Rabinovici CD, et al. *J Prev Alzheimers Dis.* 2025;12:100150. <https://doi.org/10.1016/j.tjpad.2025.100150>

All URLs accessed February 2, 2026



This activity is provided by Med Learning Group. This activity is supported by an educational grant from Lilly.